Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Ginsburg Discusses the Use of VIA in Cervical Cancer Screening

October 11th 2018

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses the use of visual inspection with acidic acid (VIA) in cervical cancer screening.

FDA Approves Gardasil 9 HPV Vaccine for Use Up to Age 45

October 7th 2018

The HPV vaccine Gardasil 9 is now approved by the FDA for use in males and females aged 9 through 45 years.

Dr. Tewari on the Trial Design With Cemiplimab in Cervical Cancer

October 4th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the trial design with cemiplimab (Libtayo) in recurrent or metastatic cervical cancer.

Cemiplimab Under Investigation in Cervical Cancer

October 3rd 2018

Krishnansu S. Tewari, MD, discusses the exploration of cemiplimab and the promise of immunotherapy in cervical cancer.

Dr. Coleman on the Future of PARP Inhibitors in Ovarian Cancer

September 29th 2018

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of PARP inhibitors in patients with ovarian cancer.

Dr. Singh on Treatment for Patients With Uterine Leiomyosarcoma

September 21st 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses treatment for patients with uterine leiomyosarcoma.

Dr. Konecny on the Value of PARP Inhibitors in Ovarian Cancer

September 19th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses studies that demonstrate the value of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Riedel on the Role of Immunotherapy in Uterine Sarcoma

September 19th 2018

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the emerging role of immunotherapy in uterine sarcoma.

Immunotherapy Could Still Have Pivotal Role in Ovarian Cancer

September 19th 2018

Matthew Powell, MD, discusses the promise of immunotherapy in ovarian cancer despite its challenges.

Coleman Covers Next Steps in Recurrent Ovarian Cancer

September 18th 2018

Robert L. Coleman, MD, FACOG, FACS, discusses the evolution of treatment for patients with ovarian cancer, the therapies with the most potential, and the importance of classification schemes in directing treatment in recurrent disease.

Dr. Secord on Personalized Treatment in Ovarian Cancer

September 15th 2018

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the growing potential for personalized treatment in ovarian cancer.

Expert Addresses Global Cervical Cancer Disparity

September 7th 2018

Ophira Ginsburg, MD, discusses cervical cancer prevention, screening, and elimination on a global scale.

PARP/Immunotherapy Combo Shows Promise in Recurrent Ovarian Cancer

September 5th 2018

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the findings of the TOPACIO/KEYNOTE-162 study and the future for PARP inhibitor combinations and immunotherapy overall in ovarian cancer.

Dr. Coleman on Classifying Patients With Ovarian Cancer

August 31st 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the classification of patients with ovarian cancer.

Dr. Riedel on the Treatment Landscape of Uterine Sarcomas

August 30th 2018

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the treatment landscape of uterine sarcomas.

Novel Agents, Genetic Testing Propel Personalized Care in Ovarian Cancer

August 29th 2018

Angeles Alvarez Secord, MD, discusses recent updates in ovarian cancer, with an emphasis on the clinical significance of genetic testing.

Dr. Secord on the Management of Patients With Sarcoma

August 28th 2018

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the management of patients with sarcoma.

Dr. Herzog on Novel Therapies in Ovarian Cancer

August 27th 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses novel therapies in ovarian cancer.

Dr. Naumann on Neoadjuvant Chemotherapy in Patients With Ovarian Cancer

August 24th 2018

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.

Dr. Powell on MSI and dMMR as Potential Biomarkers in Endometrial Cancer

August 24th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses microsatellite instability and mismatch repair deficiency as potential biomarkers in endometrial cancer.